Seasonal influenza vaccine effectiveness against laboratory-confirmed influenza in 2015–2016: a hospital-based test-negative case<b>–</b>control study in Lithuania

Kuliese, Monika; Jančorienė, Ligita; Grimalauskaitė, Rita; Zablockienė, Birutė; Damulevičienė, Gytė; Vėlyvytė, Daiva; Lesauskaitė, Vita; Ambrozaitis, Arvydas; Mickienė, Auksė; Gefenaitė, Giedrė

doi:10.1136/bmjopen-2017-017835

Cited by 6 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, we found a significant 44.6% VE against this virus, which remains similar to previous seasons (Belongia et al 2016;Darvishian et al 2017; Table 4 Absolute numbers of influenza cases and non-cases among vaccinated and unvaccinated ILI patients. Jackson et al 2017;Kuliese et al 2017). Thus, due to the high circulation of the influenza A(H1N1)pdm09 virus in Mexico, our results may provide more accurate VE estimates that may serve as a global reference about protective effectiveness of the 2016/17 influenza vaccines against this virus.…”

Section: Discussionmentioning

confidence: 87%

High performance of rapid influenza diagnostic test and variable effectiveness of influenza vaccines in Mexico

Castillejos

Cabello-Gutiérrez

Choreño-Parra

et al. 2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Objectives: To evaluate the performance of rapid influenza diagnostic tests (RIDT) and influenza vaccines' effectiveness (VE) during an outbreak setting. Methods: We compared the performance of a RIDT with RT-PCR for influenza virus detection in influenzalike illness (ILI) patients enrolled during the 2016/17 season in Mexico City. Using the test-negative design, we estimated influenza VE in all participants and stratified by age, virus subtype, and vaccine type (trivalent vs quadrivalent inactivated vaccines). The protective value of some clinical variables was evaluated by regression analyses. Results: We enrolled 592 patients. RT-PCR detected 93 cases of influenza A(H1N1)pdm09, 55 of AH3N2, 141 of B, and 13 A/B virus infections. RIDT showed 90.7% sensitivity and 95.7% specificity for influenza A virus detection, and 91.5% sensitivity and 95.3% specificity for influenza B virus detection. Overall VE was 33.2% (95% CI: 3.0-54.0; p = 0.02) against any laboratory-confirmed influenza infection. VE estimates against influenza B were higher for the quadrivalent vaccine. Immunization and occupational exposure were protective factors against influenza. Conclusions: The RIDT was useful to detect influenza cases during an outbreak setting. Effectiveness of 2016/17 influenza vaccines administered in Mexico was low but significant. Our data should be considered for future local epidemiological policies.

show abstract

Section: Discussionmentioning

confidence: 87%

High performance of rapid influenza diagnostic test and variable effectiveness of influenza vaccines in Mexico

Castillejos

Cabello-Gutiérrez

Choreño-Parra

et al. 2019

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…In our cases, the overall mortality rate was 6%, while the mortality rate was 66% for those who needed intensive care. Kuliese et al have reported the mortality rate as follows 5.6% [7] . In Korea, a mortality rate of 1.3% in adult patients hospitalized with influenza and a mortality rate of 27% in the ICU have been reported [8] .…”

Section: Discussionmentioning

confidence: 99%

“…Comorbid diseases associated with old age are also factors that increase the risk of hospitalization due to influenza. Kuliese et al reported 72 laboratory confirmed influenza positive patients, of whom 87% had at least one comorbid disease and 47% had cardiovascular disease [7] . The most common comorbidities in our study were COPD (29%) and chronic heart disease (19%).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiology and Clinical Features of Seasonal Influenza Cases Followed in Our Clinic

Türe¹,

Dursun²,

Çelik³

et al. 2018

FLORA

View full text Add to dashboard Cite

Seasonal influenza is a vaccine-preventable disease with high mortality and morbidity rate in the presence of old age, pregnancy and comorbid diseases. When we evaluated 151 patients with seasonal influenza in the 2015-2016 season, we found that the average age of the patients, comorbid diseases such as chronic obstructive pulmonary disease (COPD) and cardiovascular diseases, and the need for intensive care were high in these patients. However, only two of these patients had vaccination history. Given the reduced morbidity and mortality rates associated with vaccination and cost effectiveness, it is important to raise public awareness of vaccination, especially in the high-risk group.

show abstract

“…Influenza-positive samples were subtyped to influenza A(H1N1)pdm09, influenza A(H3N2), influenza B/Yamagata, or influenza B/Victoria. The laboratory analysis, in more detail, is described elsewhere [ 12 ].…”

Section: Methodsmentioning

confidence: 99%

Age-Specific Seasonal Influenza Vaccine Effectiveness against Different Influenza Subtypes in the Hospitalized Population in Lithuania during the 2015–2019 Influenza Seasons

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Continuous monitoring of seasonal influenza vaccine effectiveness (SIVE) is needed due to the changing nature of influenza viruses and it supports the decision on the annual update of vaccine composition. Age-specific SIVE was evaluated against different influenza subtypes in the hospitalized population in Lithuania during four influenza seasons. Methods: A test-negative case-control study design was used. SIVE and its 95% confidence intervals (95% CI) were calculated as (1 – odds ratio (OR)) × 100%. Results: Adjusted SIVE in 18–64-year-old individuals against influenza A, A(H1N1)pdm09 and B/Yamagata were 78.0% (95% CI: 1.7; 95.1%), 88.6% (95% CI: −47.4; 99.1%), and 76.8% (95% CI: −109.9; 97.4%), respectively. Adjusted SIVE in individuals aged 65 years and older against influenza A, influenza B, and B/Yamagata were 22.6% (95% CI: −36.5; 56.1%), 75.3% (95% CI: 12.2; 93.1%) and 73.1% (95% CI: 3.2; 92.5%), respectively. Unadjusted SIVE against influenza A(H3N2) among 18–64-year-old patients was 44.8% (95% CI: −171.0; 88.8%) and among those aged 65 years and older was 5.0% (95% CI: −74.5; 48.3%). Conclusions: Point estimates suggest high SIVE against influenza A in 18–64-year-old participants, and against influenza B and B/Yamagata in those 65 years old and older.

show abstract

Seasonal influenza vaccine effectiveness against laboratory-confirmed influenza in 2015–2016: a hospital-based test-negative case–control study in Lithuania

Cited by 6 publications

References 34 publications

High performance of rapid influenza diagnostic test and variable effectiveness of influenza vaccines in Mexico

High performance of rapid influenza diagnostic test and variable effectiveness of influenza vaccines in Mexico

Epidemiology and Clinical Features of Seasonal Influenza Cases Followed in Our Clinic

Age-Specific Seasonal Influenza Vaccine Effectiveness against Different Influenza Subtypes in the Hospitalized Population in Lithuania during the 2015–2019 Influenza Seasons

Contact Info

Product

Resources

About